Latest news with #HPV
Daily Mail
27 minutes ago
- Health
- Daily Mail
Revealed: Areas of UK where young people could be at greater risk of cancer linked to oral sex - do YOU live in one of them?
Almost three quarters of teens in some parts of England are missing out on a crucial anti-cancer vaccine, health officials warned today. The jab is offered to children aged 12 to 13 to protect them against human papillomavirus. Infection with the virus—also known as HPV —can trigger several types of cancers, including those in the head, neck and cervix. HPV is commonly spread through vaginal, anal and oral sex with someone who is already infected, with around a third of people infected at any one time. While a highly HPV effective vaccine has been offered to all girls in Year 8 since 2008, and all boys since 2019, latest data shows as few as a third of children in some areas of England are not getting it—leaving them vulnerable in later life. Experts have now urged parents to ensure their child gets the vaccine, labelling it 'one of the most powerful tools we have for cancer prevention'. It comes amid a documented rise in head and neck cancers, particularly among younger and middle-aged patients, which has been linked to HPV spreading via oral sex. Research has suggested that HPV may be responsible for up to 70 per cent of head and neck cancers. The virus is also responsible for almost all (99.7 per cent) of all cases of cervical cancer, a form of the disease that develops in a women's cervix. Nationally, more than one in four young people eligible for the jab haven't taken up the jab, according to data for the 2023 to 2024 academic year. But, analysis shows that uptake is far lower in certain parts of the nation. The borough of Brent in north-west London recorded the lowest HPV uptake of any local area, with only one in four girls in Year 9—aged 13 or 14—having had the jab. It was the affluent borough of Kensington and Chelsea, however, which recorded the lowest uptake for boys in Year 9—with just 25.8 per cent taking up the vaccine. Meanwhile, among Year 10 students—aged 14 or 15—vaccination levels in girls ranged from 38.7 per cent (Lambeth in London) to 97.6 per cent (Northumberland). Among boys, it ranged from 28.2 per cent (Lambeth in London) to 92.2 per cent (West Berkshire). Dr Sharif Ismail, consultant epidemiologist at UK Health Security Agency (UKHSA), said: 'The HPV vaccine, now just a single dose offered in schools, is one of the most powerful tools we have for cancer prevention. 'Every vaccination represents a young person with better protection against the devastating impact of HPV-related cancers, and we must do more to ensure that no teenage girl or boy, young woman or man is denied that protection no matter where they live. 'We're calling on all parents to return their children's HPV vaccination consent forms promptly. 'This simple action could protect your child from developing cancer in the future.' Dr Ismail said any young adult up to age 25 who missed their school jab can also speak to their GP about catch-up options. He also urged women to still attend cervical screening to ensure they are being checked for changes that could lead to cervical cancer. Cancer Research UK chief executive Michelle Mitchell added: 'Thanks to the power of research and the efforts of NHS staff, a future where almost nobody gets cervical cancer is in sight. 'This progress hinges on people's access to two life-saving offers—HPV vaccination and screening. Together, they give the best protection against the disease. 'Beating cervical cancer means beating it for everyone, so I encourage all parents and guardians to ensure young people don't miss out on getting the HPV vaccine. 'And if you receive your cervical screening invite, don't ignore it.' Dr Amanda Doyle, national director for primary care and community services at NHS England, said: 'The NHS HPV vaccination programme has already helped save thousands of lives and we need to go further to boost uptake of HPV vaccines and cervical screening to help eliminate cervical cancer in England by 2040. 'If we can ensure that almost every Year 10 girl in some areas is protected and extremely unlikely to ever develop cervical cancer, we need to match this in every part of the country.' Roughly two women in Britain every day die from cervical cancer, which famously killed TV personality Jade Goody at the age of just 27. The disease is often called a 'silent killer' because its symptoms can be easily mistaken for less serious problems, such as heavy periods and exhaustion. But if the signs are recognised early, the chance of surviving for at least five years is roughly 95 per cent. This drops to 15 per cent if the cancer is detected at later stages, when it has spread to other areas of the body. Children are offered the HPV jab in early adolescence because it is considered to be most effective if given before someone becomes sexually active. UKHSA highlighted the low rates of HPV vaccine uptake as part of Cervical Cancer Screening Awareness week. Currently women aged 25 to 49 in the UK are invited for a cervical screening check at their GP surgery every five years. They were previously offered screening every three years, but this was r ecently changed after the longer time period was found to be just as effective. For those aged between 50 and 64, it is offered every five years. Screening is arguably all the more important for women aged 34 and above, who did not receive a vaccine that protects against the vast majority of cervical cancers as part of the school programme introduced in 2008. Depending on the result of the smear test, some women may be recalled earlier than the three-year routine intervals. But screening uptake overall remains low. Only around 70 per cent of eligible women, roughly 4.6million, turn up for their scheduled test. Embarrassment is a factor, according to research by cervical cancer charities.
Yahoo
35 minutes ago
- Business
- Yahoo
Human Papillomavirus (HPV) Vaccines Strategic Business Research Report 2024-2025 & 2030 - Rising Global Awareness of HPV-Linked Cervical and Oropharyngeal Cancers Drives Preventive Vaccination Uptake
The global Human Papillomavirus (HPV) Vaccines market, valued at USD 5.5 billion in 2024, is anticipated to grow to USD 9.7 billion by 2030 at a CAGR of 9.9%. This report offers comprehensive analysis of market trends and growth drivers, providing vital insights for businesses. Key highlights include the evolution of vaccine formulations, such as nonavalent vaccines targeting multiple HPV strains, which are crucial in preventing HPV-related cancers globally. Strategic vaccination programs and improved distribution strategies are driving market expansion, particularly in emerging economies. Despite barriers like misinformation and hesitancy, increased public awareness and partnerships with organizations like Gavi are expected to enhance uptake, especially in high-burden regions. The report also assesses the impact of global tariff developments on the HPV vaccines market. Human Papillomavirus (HPV) Vaccines Market Dublin, June 19, 2025 (GLOBE NEWSWIRE) -- The "Human Papillomavirus (HPV) Vaccines - Global Strategic Business Report" report has been added to global market for Human Papillomavirus (HPV) Vaccines was estimated at US$5.5 Billion in 2024 and is projected to reach US$9.7 Billion by 2030, growing at a CAGR of 9.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Human Papillomavirus (HPV) Vaccines market. Human papillomavirus (HPV) vaccines play a central role in the prevention of HPV-related cancers, including cervical, oropharyngeal, anal, and genital cancers. With over 200 types of HPV identified and high-risk strains such as HPV-16 and HPV-18 accounting for the majority of cervical cancer cases, widespread immunization is viewed as a cornerstone of global cancer prevention strategies. These vaccines stimulate the immune system to develop antibodies against targeted viral strains, offering long-term protection against persistent infections and precancerous lesions. The Growth in the HPV Vaccines Market Is Driven by Several is driven by increasing global efforts to prevent HPV-related cancers, expansion of immunization programs, and the availability of broad-spectrum vaccine formulations. Rising public health investment in women's health and cancer prevention, along with WHO's cervical cancer elimination strategy, is catalyzing demand. The inclusion of boys in vaccination programs and growing incidence of HPV-linked head and neck cancers are further expanding the addressable progress in vaccine efficacy, long-term protection data, and potential single-dose regimens is supporting broader implementation. Additionally, partnerships between governments, vaccine developers, and health organizations are enhancing procurement, education, and infrastructure especially in emerging markets. Digital health platforms and mHealth campaigns are also improving outreach and record tracking, increasing vaccine uptake. Collectively, these trends are reinforcing HPV vaccines as a critical tool in global disease prevention and a dynamic segment within the broader vaccines Are Vaccine Formulations and Distribution Strategies Evolving?HPV vaccines have progressed from bivalent formulations (targeting HPV-16 and 18) to quadrivalent (adding protection against HPV-6 and 11) and now to nonavalent vaccines, which protect against nine HPV strains, including those responsible for up to 90% of cervical cancers. These broader-spectrum vaccines offer greater coverage and are expected to dominate future procurement and immunization programs. Continuous innovation in recombinant vaccine production and adjuvant systems is enhancing immune response and duration of is being optimized through school-based vaccination programs, gender-neutral campaigns, and integration with national childhood immunization schedules. Advances in cold-chain infrastructure, coupled with partnerships between governments, NGOs, and vaccine manufacturers, are improving access in low- and middle-income countries. Single-dose regimens are also under investigation as a cost-effective and logistically simpler alternative, with promising results that may reshape vaccination protocol and broaden global Is Uptake Increasing and What Barriers Remain?Vaccination uptake is rising in North America, Europe, and parts of Asia-Pacific where public awareness, healthcare infrastructure, and policy support are strong. Gender-neutral vaccination strategies are gaining traction, particularly in countries prioritizing the prevention of head and neck cancers linked to HPV in males. Latin America and Sub-Saharan Africa, despite high HPV burden, still face challenges including supply limitations, healthcare access gaps, and cultural include misinformation, vaccine hesitancy, and inconsistent public health messaging, particularly in conservative or resource-constrained regions. Limited adult vaccination programs and affordability issues also hamper broader market penetration. However, partnerships with organizations such as Gavi, the Vaccine Alliance, are actively addressing supply inequities and financial barriers through tiered pricing and donor-funded initiatives. As these issues are mitigated, market growth is expected to accelerate, particularly in high-burden Insights: Market Growth: Understand the significant growth trajectory of the Tetravalent segment, which is expected to reach US$5.8 Billion by 2030 with a CAGR of a 9.5%. The Nonavalent segment is also set to grow at 11.3% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $1.5 Billion in 2024, and China, forecasted to grow at an impressive 13.4% CAGR to reach $2.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Barinthus Biotherapeutics, Bharat Biotech, BioNTech SE, CanSino Biologics Inc., and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include: Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs. Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015. Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends. Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape. Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players. Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities. Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage. Key Attributes: Report Attribute Details No. of Pages 279 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $5.5 Billion Forecasted Market Value (USD) by 2030 $9.7 Billion Compound Annual Growth Rate 9.9% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Human Papillomavirus (HPV) Vaccines - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising Global Awareness of HPV-Linked Cervical and Oropharyngeal Cancers Drives Preventive Vaccination Uptake Inclusion of HPV Vaccines in National Immunization Programs Expands Coverage Across Adolescents and Young Adults WHO and GAVI Support for HPV Vaccine Rollout in Low-Income Countries Strengthens Public Health Impact Expansion of Gender-Neutral Vaccination Policies Fuels Demand Across Male and Female Populations Technological Advancements in Vaccine Formulations Improve Long-Term Efficacy and Broaden Strain Coverage Increased School-Based Immunization Drives High Compliance Rates in Developed and Emerging Regions Public-Private Partnerships and Awareness Campaigns Boost Community-Level Vaccine Acceptance Improved Cold Chain Infrastructure and Global Procurement Facilitate Distribution to Remote Areas Rising Incidence of HPV-Associated Head and Neck Cancers Spurs Broader Advocacy for Adult Vaccination Growing Market Entry of Biosimilar and Region-Specific HPV Vaccines Enhances Accessibility and Affordability FOCUS ON SELECT PLAYERS Barinthus Biotherapeutics Bharat Biotech BioNTech SE CanSino Biologics Inc. GlaxoSmithKline plc Inovio Pharmaceuticals Johnson & Johnson Merck & Co., Inc. Moderna, Inc. Novavax, Inc. Pfizer Inc. Sanofi S.A. Serum Institute of India Sinovac Biotech Ltd. Takeda Pharmaceutical Company Valneva SE Vaxart, Inc. Walvax Biotechnology Co., Ltd. Wantai BioPharm Xiamen Innovax Biotech Co., Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Human Papillomavirus (HPV) Vaccines Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Scottish Sun
2 hours ago
- Health
- Scottish Sun
Women at risk of ‘preventable' cancer due to ‘alarmingly' low uptake of ‘life-saving' jab, health chiefs warn
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) YOUNG women are at higher risk of a "preventable" cancer due to "alarmingly" low uptake of life-saving NHS jabs, health chiefs have warned. Human papillomavirus (HPV) vaccines are dished out to 12 and 13-year-olds and offer protection against cancer-causing strains of the virus. Sign up for Scottish Sun newsletter Sign up 2 Low uptake oh HPV vaccines in certain parts of the country leaves young women vulnerable to cancer Credit: AP But low uptake of jabs in certain parts of England is leaving young women vulnerable to cervical cancer and other forms of the disease caused by HPV. HPV is a common virus that's spread through skin contact, usually during sex. Most strains are harmless but some high-risk ones can increase people's chances of developing cervical cancer, as well as mouth, anal, penile, vulval and vaginal cancer. Around 13 high-risk types of HPV are known to cause 99.7 per cent of cervical cancers. Health bosses have made it their mission to eliminate cervical cancer in England by 2040. But despite efforts to increase vaccine uptake in teens, the latest data published by the UK Health Security Agency (HPV) shows gaps in coverage in certain parts of the country, leaving young women in these areas at higher risk of HPV-related cancer. The data on HPV coverage in teens for 2023/24 showed that only 64.9 per cent of Year 10 female students in London had received their jabs. Coverage was also low for boys of the same age in the capital, with only 59 per cent taking up the offer for an HPV vaccine. Meanwhile, HPV coverage was highest in the South East for both genders - where 82.7 per cent of girls and 77.3 per cent of boys had gotten vaccinated by Year 10. At local authority level, Year 10 vaccination levels in girls ranged from 38.7 per cent in Lambeth, South London, to 97.6 per cent in Northumberland. Cervical cancer could be eradicated as HPV vaccine slashes 90% of cases For boys, it ranged from 28.2 per cent in Lambeth to 92.2 per cent in West Berkshire. Cervical cancer rates are already 65 per cent higher in England's most deprived areas compared with the least, according to figures from Cancer Research UK. Dr Sharif Ismail, consultant epidemiologist at UKHSA, said: "The HPV vaccine, now just a single dose offered in schools, is one of the most powerful tools we have for cancer prevention. "Every vaccination represents a young person with better protection against the devastating impact of HPV-related cancers and we must do more to ensure that no teenage girl or boy, young woman or man is denied that protection no matter where they live. "Although we have seen some increase in the number of young people being vaccinated, uptake is still well below pre-Covid pandemic levels "Over a quarter of young people - many thousands - are missing out on this potentially life-saving vaccine." The HPV jab is given to boys and girls when they are in Year 8, though some children receive it in Year 9. It delivers a significantly stronger immune response if given before the age of 16, though getting it when older as part of a catch-up programme still creates a strong response. 2 Anyone who missed their HPV vaccination, now just a single jab, can still receive it for free until their 25th birthday through their GP surgery. Up until recently, the HPV jab was only offered to girls. But boys also have an important role to play in helping eliminate cervical cancer by being vaccinated and not passing on the HPV virus when they become sexually active, UKHSA said. Jabs were rolled out to teenage boys in 2019. 'Beat cancer for everyone' Dr Ismail said: "We're calling on all parents to return their children's HPV vaccination consent forms promptly. "This simple action could protect your child from developing cancer in the future." Dr Ismail said any young adult up to age 25 who missed their school jab can speak to their GP about catch-up options. He also urged women to still attend cervical screening to ensure they are being checked for changes that could lead to cervical cancer. "Even if you've had the HPV vaccine, it's vital you still attend your cervical screening appointments when invited," Dr Ismail said. "Both vaccination and screening together give you your best chance of protection against cervical cancer. "Screening can detect abnormal cells before they develop into cancer, allowing for early treatment and prevention." It comes after UKHSA warned earlier this year that over a quarter of schoolkids hadn't had their HPV jab. Cancer Research UK chief executive Michelle Mitchell said: "Thanks to the power of research and the efforts of NHS staff, a future where almost nobody gets cervical cancer is in sight. "This progress hinges on people's access to two life-saving offers - HPV vaccination and screening. Together, they give the best protection against the disease. "Beating cervical cancer means beating it for everyone, so I encourage all parents and guardians to ensure young people don't miss out on getting the HPV vaccine. "And if you receive your cervical screening invite, don't ignore it." Dr Amanda Doyle OBE, national director for primary care and community services at NHS England, said: "The NHS HPV vaccination programme has already helped save thousands of lives and we need to go further to boost uptake of HPV vaccines and cervical screening to help eliminate cervical cancer in England by 2040. "If we can ensure that almost every Year 10 girl in some areas is protected and extremely unlikely to ever develop cervical cancer, we need to match this in every part of the country. "It's vital for boys and young men to be vaccinated too. Rates in boys still lag behind girls and HPV causes thousands of cancers in men as well as things like genital warts."
The Sun
2 hours ago
- Health
- The Sun
Women at risk of ‘preventable' cancer due to ‘alarmingly' low uptake of ‘life-saving' jab, health chiefs warn
YOUNG women are at higher risk of a "preventable" cancer due to "alarmingly" low uptake of life-saving NHS jabs, health chiefs have warned. Human papillomavirus (HPV) vaccines are dished out to 12 and 13-year-olds and offer protection against cancer-causing strains of the virus. 2 But low uptake of jabs in certain parts of England is leaving young women vulnerable to cervical cancer and other forms of the disease caused by HPV. HPV is a common virus that's spread through skin contact, usually during sex. Most strains are harmless but some high-risk ones can increase people's chances of developing cervical cancer, as well as mouth, anal, penile, vulval and vaginal cancer. Around 13 high-risk types of HPV are known to cause 99.7 per cent of cervical cancers. Health bosses have made it their mission to eliminate cervical cancer in England by 2040. But despite efforts to increase vaccine uptake in teens, the latest data published by the UK Health Security Agency (HPV) shows gaps in coverage in certain parts of the country, leaving young women in these areas at higher risk of HPV-related cancer. The data on HPV coverage in teens for 2023/24 showed that only 64.9 per cent of Year 10 female students in London had received their jabs. Coverage was also low for boys of the same age in the capital, with only 59 per cent taking up the offer for an HPV vaccine. Meanwhile, HPV coverage was highest in the South East for both genders - where 82.7 per cent of girls and 77.3 per cent of boys had gotten vaccinated by Year 10. At local authority level, Year 10 vaccination levels in girls ranged from 38.7 per cent in Lambeth, South London, to 97.6 per cent in Northumberland. Cervical cancer could be eradicated as HPV vaccine slashes 90% of cases For boys, it ranged from 28.2 per cent in Lambeth to 92.2 per cent in West Berkshire. Cervical cancer rates are already 65 per cent higher in England 's most deprived areas compared with the least, according to figures from Cancer Research UK. Dr Sharif Ismail, consultant epidemiologist at UKHSA, said: "The HPV vaccine, now just a single dose offered in schools, is one of the most powerful tools we have for cancer prevention. "Every vaccination represents a young person with better protection against the devastating impact of HPV-related cancers and we must do more to ensure that no teenage girl or boy, young woman or man is denied that protection no matter where they live. "Although we have seen some increase in the number of young people being vaccinated, uptake is still well below pre-Covid pandemic levels "Over a quarter of young people - many thousands - are missing out on this potentially life-saving vaccine." The HPV jab is given to boys and girls when they are in Year 8, though some children receive it in Year 9. It delivers a significantly stronger immune response if given before the age of 16, though getting it when older as part of a catch-up programme still creates a strong response. Anyone who missed their HPV vaccination, now just a single jab, can still receive it for free until their 25th birthday through their GP surgery. Up until recently, the HPV jab was only offered to girls. But boys also have an important role to play in helping eliminate cervical cancer by being vaccinated and not passing on the HPV virus when they become sexually active, UKHSA said. Jabs were rolled out to teenage boys in 2019. 'Beat cancer for everyone' Dr Ismail said: "We're calling on all parents to return their children's HPV vaccination consent forms promptly. "This simple action could protect your child from developing cancer in the future." Dr Ismail said any young adult up to age 25 who missed their school jab can speak to their GP about catch-up options. He also urged women to still attend cervical screening to ensure they are being checked for changes that could lead to cervical cancer. "Even if you've had the HPV vaccine, it's vital you still attend your cervical screening appointments when invited," Dr Ismail said. "Both vaccination and screening together give you your best chance of protection against cervical cancer. "Screening can detect abnormal cells before they develop into cancer, allowing for early treatment and prevention." It comes after UKHSA warned earlier this year that over a quarter of schoolkids hadn't had their HPV jab. Cancer Research UK chief executive Michelle Mitchell said: "Thanks to the power of research and the efforts of NHS staff, a future where almost nobody gets cervical cancer is in sight. "This progress hinges on people's access to two life-saving offers - HPV vaccination and screening. Together, they give the best protection against the disease. "Beating cervical cancer means beating it for everyone, so I encourage all parents and guardians to ensure young people don't miss out on getting the HPV vaccine. "And if you receive your cervical screening invite, don't ignore it." Dr Amanda Doyle OBE, national director for primary care and community services at NHS England, said: "The NHS HPV vaccination programme has already helped save thousands of lives and we need to go further to boost uptake of HPV vaccines and cervical screening to help eliminate cervical cancer in England by 2040. "If we can ensure that almost every Year 10 girl in some areas is protected and extremely unlikely to ever develop cervical cancer, we need to match this in every part of the country. "It's vital for boys and young men to be vaccinated too. Rates in boys still lag behind girls and HPV causes thousands of cancers in men as well as things like genital warts." Everything you need to know about the HPV vaccine The HPV vaccine protects against some of the risky HPV types that can lead to genital warts and cancer. Gardasil has been the HPV vaccine used in the NHS vaccination programme since 2012. It is protective against nine types of HPV. For example it is effective against types 16 and 18 which cause around 80 per cent of cervical cancers in the UK. That's why it is important for people who have a cervix to still get a smear test when invited by the NHS. Cervical cancer takes the lives of 854 people a year currently - but this is expected to continue decreasing thanks to the vaccine. There are around 3,200 new cases of the devastating cancer a year, with peak incidence in women in their early 30s. But the HPV vaccine doesn't just prevent cervical cancer - it stops some anal, genital (vaginal and penile), mouth and throat (head and neck) cancers. These affect both men and women. Who should take it? The first dose of the HPV vaccine is routinely offered to girls and boys aged 12 and 13 in school Year 8. The second dose is offered 6 to 24 months after the 1st dose. If a school child misses their doses, you can speak to the school jab team or GP surgery to book as soon as possible. Anyone who missed their jab can get it up to their 25th birthday. But people who have the first dose of the HPV vaccine at 15 years of age or above will need to have three doses of the vaccine because they do not respond as well to two doses as younger people do. The HPV vaccine used to only be given to girls who are at risk of cervical cancer when they are older. But in 2018, it was announced that boys - who can get HPV-related cancers of the head, nech, anal and genitals - would also be given a jab. Girls indirectly protect boys against HPV related cancers and genital warts because girls will not pass HPV on to them. But the programme was extended to further eliminate risk of the virus spreading in the future. Men who have sex with men (gay and bisexual) do not benefit from this indirect protection, and so are also able to get the HPV vaccine up to the age of 45. Some transgender people can also get the vaccine. Those assigned female at birth would have gotten one as a child. But those assigned male at birth could get a jab if they transition to female and have sex with men.
Yahoo
2 hours ago
- Health
- Yahoo
Transgene completes initial screening in Phase II part of TG4050 vaccine trial
Transgene has completed the initial subject screening for the Phase II segment of its Phase I/II trial of individualised neoantigen therapeutic vaccine, TG4050, as a monotherapy in the adjuvant treatment of human papillomavirus (HPV)-negative squamous head and neck cancers. The vaccine is based on the myvac platform powered by its partner NEC's AI to enhance antigen selection. During the Phase I portion of the trial, all subjects treated with the vaccine remained disease-free post a minimum follow-up of two years, demonstrating clinical proof of principle. Translational data indicated that these subjects showed sustained T cell responses at 24 months. Meeting all trial endpoints, the findings were shared at the American Society of Clinical Oncology (ASCO 2025) annual meeting. The company anticipates completing the randomisation of all subjects in the Phase II part by the end of this year, after a second screening carried out post-surgery and adjuvant radiotherapy. Around 80 subjects who have completely responded to adjuvant therapy are expected to be enrolled and randomised in the Phase I/II trial. The first immunogenicity data from the Phase II part are projected to be available in the second half of 2026, with preliminary efficacy data anticipated in the second half of 2027. The trial is assessing the treatment benefits of the vaccine in individuals at risk of relapse. So far, 32 evaluable patients have been included in the Phase I part, with the Phase II continuing globally. Transgene chief medical officer Dr Emmanuelle Dochy said: 'Timely completion of first patient screening of the Phase II part of our Phase I/II trial is an important milestone for Transgene and brings us one step closer to providing a new treatment option for patients living with operable squamous head and neck cancer. 'With meaningful data readouts expected over the next two years, we are preparing to deliver important data for TG4050 and, at the same time, explore its wider potential. We are grateful to the patients, their families, investigators, and clinical staff whose commitment made this achievement possible.' "Transgene completes initial screening in Phase II part of TG4050 vaccine trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
